Cognitive and Histological Methodological Framework for an Intrahippocampal Aβ1-42 Rat Model of Alzheimer's Disease
- Neurol Int. 2026 Apr 24;18(5):79. doi: 10.3390/neurolint18050079.
- 1. Department of Neurosurgery, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
- 2. Department of Neurosurgery, "Prof. Dr. N. Oblu" Emergency Clinical Hospital, 700115 Iasi, Romania.
- 3. Advanced Research and Development Center for Experimental Medicine "Prof. Ostin C. Mungiu"-CEMEX, Grigore T. Popa University of Medicine and Pharmacy Iasi, 700115 Iasi, Romania.
Background: Standardized and ethically compliant animal models remain essential for improving translational research in Alzheimer's disease. Although Aβ1-42-induced rodent models are widely used, methodological variability continues to limit reproducibility.
Methods: We explored the feasibility of a stereotactic intrahippocampal Aβ1-42 rat model established by bilaterally injecting pre-aggregated peptide into the hippocampus of adult Sprague Dawley rats. Model feasibility and targeting accuracy were assessed intraoperatively. Cognitive performance was evaluated using the Y-maze for spatial recognition memory and the novel object recognition (NOR) test. Histological examination was performed using hematoxylin-eosin (H&E) and Congo red staining to assess cytoarchitecture and to provide supportive evidence of amyloid-like deposits.
Results: The surgical procedure was well-tolerated, and the injected Animals showed reduced performance in behavioural testing, including reduced spatial recognition memory in the Y-maze and decreased discrimination indices in the NOR test. The Animals also showed histological changes, including Congo red-positive birefringent structures consistent with amyloid-like congophilic material.
Conclusions: This study presents a feasible experimental framework for intrahippocampal Aβ1-42 administration, showing behavioural and histological changes under the present experimental conditions. However, further validation, including sham-operated controls and molecular characterization, will be required before these findings can be interpreted as specific to Aβ-driven pathology.
-
Cat. No.Product NameDescriptionTargetResearch Area
-
target: Amyloid-βResearch Areas: Neurological Disease